Staar Surgical CO Form 4 insider transactions

Warren Foust, President and CEO of Staar Surgical Co, reported multiple transactions in common stock on July 31, 2026.

STAAR Surgical Company reports a Director, Lilian Y. Zhou, acquired 3,530 shares of common stock on June 12, 2026.

Deborah J. Andrews, Interim Co-CEO and CFO of STAAR Surgical Co., reported transactions involving performance stock units and common stock.

Warren Foust, Interim Co-CEO and Pres. & COO of STAAR SURGICAL CO, reported transactions involving performance stock units and common stock on May 15, 2026.

Magda Michna, Chief Development Officer at STAAR SURGICAL CO, reported the vesting of performance stock units on May 15, 2026, with a portion withheld for taxes.

STAAR Surgical Co. executive Warren Foust reported a disposition of common stock to cover tax obligations related to vested restricted stock units.

STAAR Surgical Co. reports a transaction where Chief Development Officer Magda Michna sold shares to cover tax obligations.

STAAR Surgical's Interim Co-CEO and CFO, Deborah J. Andrews, was granted 39,809 restricted stock units vesting over three years.

STAAR SURGICAL's Interim Co-CEO and President & COO, Warren Foust, reported the acquisition of common stock through RSU vesting and a new RSU grant.

STAAR SURGICAL's Chief Development Officer, Magda Michna, reported the vesting of restricted stock units and subsequent tax-related share disposals.

Broadwood Partners and affiliated insiders significantly increased their beneficial ownership in STAAR Surgical Co. through open market purchases.

STAAR Surgical Co. awarded 20,787 restricted stock units to Interim Co-CEO and President & COO Warren Foust in connection with his appointment.

STAAR Surgical Co. granted 20,787 restricted stock units to Deborah J. Andrews, Interim Co-CEO and CFO, in connection with her appointment.

STAAR Surgical Director Wei Jiang reported the vesting of 20,967 restricted stock units, converting to common stock, as part of his compensation for strategic advisory services.

Broadwood Partners, a 10% owner and director, acquired additional common stock in STAAR Surgical Co. on January 9, 2026.

Broadwood Partners, a 10% owner and director, significantly increased its beneficial ownership in STAAR Surgical Co. through multiple open market purchases.

STAAR Surgical's Chief Legal Officer, Nathaniel Sisitsky, reported the vesting of 7,312 restricted stock units, with 2,616 shares withheld for tax obligations.

Broadwood Partners, a 10% owner and director, significantly increased its beneficial ownership in STAAR Surgical Co. through multiple common stock purchases in November 2025.

STAAR Surgical Director Wei Jiang reported the vesting of 20,967 restricted stock units, increasing his direct beneficial ownership of common stock.

STAAR Surgical director Wei Jiang's restricted stock units vested, adding 20,967 shares to his direct beneficial ownership.

STAAR Surgical Company's new Chief Financial Officer, Deborah J. Andrews, was granted 41,867 Restricted Stock Units (RSUs) on June 25, 2025, as part of her compensation.

STAAR Surgical Co. Director Lilian Y. Zhou was granted 4,363 stock options with an exercise price of $16.72 as part of her annual non-employee director equity compensation.

STAAR Surgical Co. Director Lou Silverman was granted 10,683 restricted stock units as part of the company's non-employee director equity compensation program.

STAAR Surgical Co. Director Wei Jiang was granted 10,683 restricted stock units as part of the company's annual non-employee director equity compensation program.

STAAR Surgical Co. Director Lilian Yansheng Zhou was granted 19,415 stock options as part of the company's annual non-employee director equity compensation program.

STAAR Surgical Co. Director Arthur C. Butcher was granted 5,341 Restricted Stock Units and 9,708 Common Stock Options as part of the company's annual non-employee director equity compensation program.

STAAR Surgical Co. Director Elizabeth Yeu was granted 5,341 Restricted Stock Units and 9,708 Common Stock Options on June 18, 2025, as part of the company's routine non-employee director equity compensation program.

Magda Michna, Chief Development Officer at STAAR Surgical, reports disposition of shares to cover tax obligations following RSU vesting.

Director Louis Silverman acquired 2,440 stock options in STAAR Surgical Co. on May 12, 2025, according to a Form 4 filing.

Wei Jiang, a director at STAAR Surgical, received 62,901 restricted stock units (RSUs) on May 12, 2025, in connection with his role as a special strategic advisor to the Corporation's Asia Pacific business.